Boglarka Gyurkocza, MD

Boglarka Gyurkocza, MD

Reducing Relapse of Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

We are conducting two clinical trials with novel, minimally toxic conditioning regimens – combining treosulfan or clofarabine, instead of fludarabine, with hematopoietic cell transplantation (HCT). Our goal is to reduce the incidence of recurrent leukemia following HCT, thereby increasing the likelihood of long-term survival.